Niagen Bioscience Inc
NAGEHealthcare|Biotechnology|US
$2.07
-0.04 (-1.66%)
Tangible Book / Share
$0.98
Graham Number
$1.75
Next Earnings Report
Mar 3, 2027
EPS est. -$0.04 · Revenue est. $33.2M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (0)
No upcoming completion dates found in active trials.
Recent Press Releases
Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results
Nov 4, 2026 · Business Wire
Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion
Oct 22, 2026 · Business Wire
Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product
Oct 20, 2026 · Business Wire
Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
Oct 15, 2026 · Business Wire
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)
Oct 8, 2026 · Business Wire
Niagen Bioscience to Present at LD Micro 20th Annual Main Event
Oct 6, 2026 · Business Wire
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.
Oct 1, 2026 · Business Wire
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
Sep 30, 2026 · Business Wire